Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Related Videos
Experts on renal cell carcinoma
Experts on renal cell carcinoma
Matthew Galsky, MD
Expert on prostate cancer
Jonathan Chatzkel, MD
David A. Braun, MD, PhD
Paul L. Nguyen, MD, senior physician, director, Genitourinary Clinical Center for Radiation Oncology, Dana-Farber Cancer Institute, professor of radiation oncology, Harvard Medical School,
Guru P. Sonpavde, MD, medical director, Genitourinary (GU) Oncology, assistant director, Clinical Research Unit, Christopher K. Glanz Chair, Bladder Cancer Research, AdventHealth Cancer Institute
Related Content

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023